Skip to main content

Medical Oncology

Ausgabe 11/2022

Inhalt (21 Artikel)

Open Access Original Paper

Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy

Yixiao Sun, Xueran Guan, Ting Zhang, Yue Li, Huiling Shi, Ashleigh Tinotenda Chitakunye, Hanyu Hong, Shihui Zhang, Qin Zhu, Lin Cai

Original Paper

A novel approach to develop an animal model for oral submucous fibrosis

Madhura Shekatkar, Supriya Kheur, Avinash Sanap, Vaishali Undale, Avinash Kharat, Vrushali Bhalchim, Arati Dubewar, Ramesh Bhonde

Original Paper

Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells

Mina Afrashteh Nour, Fatemeh Kheradmand, Yousef Rasmi, Behzad Baradaran

Open Access Original Paper

Matrine induces autophagy in human neuroblastoma cells via blocking the AKT-mTOR pathway

Nanjing Liu, Chunmei Yang, Li Yang, Ting Li, Maoyuan Gong, Haobiao Wang, Jun Zhang, Hui Zhao, Lin Zou, Xiaoyan He

Original Paper

SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells

Chuanbo Ha, Lihong Hu, Yuanyuan Ren, Jie Yang, Lingbiao Xin

Original Paper

The inhibitory effect of betulinic acid on epithelial–mesenchymal transition pathway in renal cell carcinoma

Merve Nur Ataş, Barış Ertuğrul, Elif Sinem İplik, Bedia Çakmakoğlu, Arzu Ergen

Original Paper

Synthesis, characterization, antioxidant and anticancer activities of a new Schiff base and its M(II) complexes derived from 5-fluorouracil

Ahmet Savcı, Kenan Buldurun, Mehmet Eşref Alkış, Yusuf Alan, Nevin Turan

Original Paper

CRISPR/Cas9-mediated knockout of HO-1 decreased the proliferation and migration of T47D cells and increased cisplatin-induced apoptosis: an in vitro study

Sahar Evazi Bakhshi, Amaneh Mohammadi Roushandeh, Mehryar Habibi Roudkenar, Shima Shekarchi, Mohammad Hadi Bahadori

Original Paper

Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library

Nasir Shams, Shahryar Khoshtinat Nikkhoi, Zhanjun Gu, Fatemeh Rahbarizadeh

Original Paper

Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:—an in silico and in vitro approach

Ravinder Doneti, Akbar Pasha, Mahendran Botlagunta, S. K. Heena, Veera Venkata Vara Prasad Mutyala, Smita C. Pawar

Open Access Perspectives in Oncology

Origin and evolution of animal multicellularity in the light of phylogenomics and cancer genetics

Florian Jacques, Etienne Baratchart, Kenneth J. Pienta, Emma U. Hammarlund

Review Article

Genetic insights into cardiac tumors: a comprehensive review

Sivaramasundaram Sankarasubramanian, Prathiksha Prabhakar, Manoj Kumar Narasimhan

Review Article

Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon

Anna La Salvia, Irene Persano, Elena Parlagreco, Alessandro Audisio, Massimiliano Cani, Maria Pia Brizzi

Review Article

Differential molecular mechanistic behavior of HDACs in cancer progression

Tashvinder Singh, Prabhsimran Kaur, Paramdeep Singh, Sandeep Singh, Anjana Munshi

Review Article

RNA splicing: a dual-edged sword for hepatocellular carcinoma

Anjali Kashyap, Greesham Tripathi, Avantika Tripathi, Rashmi Rao, Manju Kashyap, Anjali Bhat, Deepak Kumar, Anjali Rajhans, Pravindra Kumar, Darshan Shimoga Chandrashekar, Riaz Mahmood, Amjad Husain, Hatem Zayed, Alok Chandra Bharti, Manoj Kumar Kashyap

Open Access Review Article

Clinical value and molecular mechanism of AQGPs in different tumors

Rui Wang, Xuejian Wang, Jun Zhao, Jiacheng Jin, Weiwei Fan, Xinqing Zhu, Qiwei Chen, Baochang Zhang, Lan Lan, Kexin Qu, Liang Zhu, Jianbo Wang

Review Article

Decoding the mechanism of vascular morphogenesis to explore future prospects in targeted tumor therapy

Gayathri Venkatakrishnan, Venkatachalam Deepa Parvathi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.